STOCK TITAN

Guardant Health Inc - GH STOCK NEWS

Welcome to our dedicated news page for Guardant Health (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.

Rhea-AI Summary
Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
partnership
-
Rhea-AI Summary
Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
partnership
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) appoints Terilyn Juarez Monroe as Chief People Officer to lead human resources, talent acquisition, and diversity and inclusion initiatives. Monroe brings extensive experience from previous roles at Bonterra, Varian, Acxiom, and Intuit, with a focus on scaling and developing world-class teams and cultures. She aims to support Guardant's mission to revolutionize cancer screening and detection, providing patients with more quality time with their families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
management
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) has entered into a common stock purchase agreement with Baillie Gifford for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share, resulting in gross proceeds of approximately $90.7 million. The net proceeds will be used primarily for general corporate purposes, including working capital, operating expenses, and capital expenditures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
offering
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will present and participate in a Q&A session on Monday, January 8, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties can access live and archived webcasts of the sessions on the 'Investors' section of the company website at www.guardanthealth.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
conferences
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) announced that the U.S. FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for its Shield™ blood test to screen for colorectal cancer on March 28, 2024. The submission includes data from the company’s positive ECLIPSE study, an over 20,000-patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.61%
Tags
none
Rhea-AI Summary
Cancer Research UK (CRUK) and Guardant Health, Inc. (Nasdaq: GH) have announced a collaboration to explore opportunities to accelerate the discovery and development of cancer drugs and diagnostics. The partnership will focus on sharing technologies, data, and insights to advance precision oncology, with a particular emphasis on CRUK's clinical trials, including the DETERMINE trial - the first UK national precision medicine trial in rare cancers. Guardant Health aims to further validate its technologies, including the InfinityTM platform, while providing support for those with rare cancers and others who could benefit from precision oncology. The collaboration also aims to apply data-driven insights and technologies to CRUK's detection and treatment studies, potentially accelerating the work of the Centre for Drug Development and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
clinical trial
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will present data at the San Antonio Breast Cancer Symposium, highlighting the role of blood tests in detecting minimal residual disease and predicting therapy response in breast cancer patients. The presentations will showcase the use of liquid biopsy tests to identify actionable biomarkers and predict recurrence in early-stage breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) announces the grant of 50,741 restricted stock units (RSUs) to 43 new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest on an annual basis, subject to each employee’s continued employment with Guardant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) to Appeal Verdict on Intellectual Property Claims
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
none
Guardant Health Inc

Nasdaq:GH

GH Rankings

GH Stock Data

2.51B
116.66M
4.15%
92.19%
6.37%
Dental Laboratories
Manufacturing
Link
United States
Palo Alto

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.